Novo Nordisk and Ro announce research collaboration on Wegovy pill real-world evidence

Novo Nordisk and Ro entered a research collaboration to generate real-world evidence on the oral Wegovy (semaglutide) pill in patients with overweight or obesity. Initial data from patients switching from injectable GLP-1s was presented at EASD2026; additional analyses on demographics, weight loss, food noise, and quality of life will be presented at ObesityWeek 2026.

主要事実

提出: 2026年9月30日 17:45
イベント: 提携・ライセンス契約
方向: 中立
企業: NVOノボノルディスク
アセット: semaglutide
出典: 企業プレスリリース
信頼度: 出典あり
発表日: 9月30日 EASD2026; 11月14-17日 ObesityWeek 2026

出典の抜粋

Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill News provided by Ro Sep 30, 2026, 05:45 ET Share this article Share to X Share this article Share to X Debut research presented at EASD2026 reveals outcomes among patients on Ro's platform who switched from an injectable GLP-1 to the Wegovy® pill NEW YORK , Sept. 30, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Novo that will generate first-of-its-kind real-world evidence on the Wegovy® pill. The debut research from the collaboration, presented on September 30 at EASD2026 in Milan,

企業プレスリリース

このアセットの詳細

2026年9月29日

18:00

NVOノボノルディスク

Novo Nordisk: Ozempic 2 mg shows lower MACE risk vs tirzepatide switch in real-world EASD analysis

学会発表企業プレスリリース2 件の更新